Protocol Ledger

NCT03201458 · Phase II · COMPLETED

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

Interventional Phase II clinical trial protocol NCT03201458 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-02-08 Enrollment: 86 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03201458
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)86 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03201458
Protocol FieldVerified Registry Value
NCT IdentifierNCT03201458
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment86 participants (ACTUAL)
Registered Start Date2018-02-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI